ANDA 205540, held by Gland. Levofloxacin.
As of Nov 16, 2026, ANDA 205540 (Levofloxacin), held by Gland, was first approved by FDA on Apr 22, 2020, with 1 approved supplement and 0 published complete response letters.
Levofloxacin Injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1, 12.4 ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2020 | Original application | Approved | None posted |
| LevofloxacinEQ 500MG/20ML (EQ 25MG/ML) · injectable;injection | Levofloxacin | Rx |
| LevofloxacinEQ 750MG/30ML (EQ 25MG/ML) · injectable;injection | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 22, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters